Abstract
A. baumannii is recognised as an important etiologic agent for hospital infections and increases the risk of postoperative complications, worsening mortality and prolonging hospitalisation. Protegrin-1 (PG-1) is one of the most promising antimicrobial peptides (AMPs) in the literature, since its antimicrobial action covers a wide range of Gram-positive and Gram-negative bacteria, including A. baumannii. PG-1 represents a valid new therapeutic option for the treatment of A. baumannii multi-drug resistant infections, showing synergic activity with traditional antibiotics, such as colistin. However, its clinical use in humans still requires studies, especially considering the haemolytic risk. For this reason, the use of PG-1 analogues, such as PLP-3, HV2, CDP-1, and IB367, seems to be the most promising way for the clinical use of this class of AMPs.